 |
CareScience Pharma & Biotech Services
CareScience
Pharmaceutical Services provide critical analysis of clinical
information that is a powerful resource for pharmaceutical
and biotechnology companies. Our decade long experience with
and knowledge of inpatient care provides a strong platform
for our data analysis services.
We
draw upon our expertise in care management and quality improvement
by offering customized data studies by therapeutic area, disease
category, drug or condition of interest. Through our services,
we offer pharma and biotech companies insight into their product
profiles by conducting study designs that increase the likelihood
for continued clinical and commercial success throughout the
drug development cycle. These studies can help pharma and
biotech clients:
- Improve
their understanding of their drug market
- Assess
the size of their market
- Measure
real-world drug effectiveness
- Gain
insights and answers into diseases, treatments, outcomes
and economic impact
- Gather
and assess better information across disease areas, diagnoses,
procedures, drugs and geographic distribution
- Assess
disease management protocols – see how physicians are treating
patients with a certain disease or group of particular diseases/complications
- Study
demographic characteristics and treatment patterns of patients
admitted to hospitals for a particular disease - analyze
disease patterns or identify procedure, device and drug
utilization
- Review
current medication practices
- Assess
economic and clinical outcomes for a drug
- Analyze
resource utilization and outcomes
- Profile
disease and treatment trends - project how often a disease
appears in an inpatient setting
- Capture
geographic disparities in care and drug utilization that
will help inform regional marketing campaigns
- Examine
biases in the inpatient setting that affect practice patterns
and drug utilization
- Conduct
market intelligence on competitor drugs - how frequently
a drug is given and in what circumstances
- Monitor
the utilization rates and patterns of competitor drugs
|
|
|
